Back to News
Dec 8, 2025 12:00 PM

Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer

Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of Hematology (ASH) Annual Meeting.

The preliminary analysis (data cut off September 25, 2025) evaluated the safety and efficacy of INCA033989 in myelofibrosis (MF) patients with as measured by spleen volume reduction ≥25% (SVR25) and ≥35% (SVR35), change in MPN-Symptom Assessment Form (SAF), total symptom score (TSS), anemia response and mutCALR variant allele frequency (VAF) reduction.

Exploratory analyses from the clinical studies of INCA033989 demonstrate the potential for disease-modifying activity in MF patients with a CALR mutation, the company said in a press release.

Also Read: FDA Expands Incyte’s Opzelura Approval To Treat Atopic Dermatitis In Children

Monotherapy Arm of the Trials

In the monotherapy arms, patients treated with INCA033989 experienced rapid and robust spleen and anemia responses and symptom improvements.

At Week 24, 41.7% of ...